GLPwatch
Rybelsus for Smoking cessation
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCRybelsus (semaglutide) is not FDA-approved for smoking cessation, and any use for this purpose is off-label or investigational. A study protocol examines semaglutide’s potential to limit weight gain after quitting smoking, but no completed research is cited.
AI summary of the sources below.
| Drug | Rybelsus (semaglutide) |
|---|---|
| Condition | Smoking cessation |
| Approval status | Investigational / off-label |
| Research papers | 3 |
Rybelsus is not FDA-approved for smoking cessation; the research below reflects investigational or off-label study only.
Research on semaglutide for smoking cessation (3)
- Semaglutide and smoking cessation in individuals with type 2 diabetes mellitus: there is no smoke without fire!
- Semaglutide: A New Medical Swiss Army Knife?
- A randomized controlled trial of once-weekly semaglutide for limiting post-smoking cessation weight gain in smokers with overweight/obesity: Study protocol.